|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of external Sanjierupi Gao on mastalgia caused by mammary gland hyperplasia: a placebo controlled trial显示文摘OBJECTIVE:To evaluate the curative effect of external application of the Chinese drug,Sanjierupi Gao,on mastalgia caused by mammary gland hyperplasia.METHODS:This randomized,double-blinded,and placebo controlled study enrolled 260 patients with mammary gland hyperplasia from five hospitals.Patients were randomly and equally divided in-to a Sanjierupi Gao treatment group and a placebo control group.An adhesive plaster was applied to the most painful area on either breast for 7 h a day.Treatment lasted for two menstrual cycles without application during menstruation.Mastalgia was used as the main index of curative effect.The change before and after treatment in days of mastalgia,the time to alleviate pain,pain extent,and severe pain scores were observed.RESULTS:Compared to the control group,the treatment group had significantly fewer days of mastalgia(P<0.01),a significantly lower severe pain score(P<0.01),and significantly less subjective pain and tenderness(P<0.05 and P<0.01,respectively).Three days before the follow-up visit,the pain score in the treatment group was significantly lower than that in the control group(P<0.05).A non-parametric test was used to compare the time to alleviate mastalgia between the two groups and found no statistical difference(Z=0.313,P=0.754).CONCLUSION:Application of Sanjierupi Gao can decrease mastalgia duration in patients with mammary gland hyperplasia during menstruation and alleviate the extent of mastalgia.The time to alleviate pain is psychologically influenced. | Yingyi Fan Xiaohua Pei Zhaolan Liu Zhongyuan Xia Dongxiao Zhang Afeng Song Duo Liu | 2013 | Journal of Traditional Chinese Medicine2013，33，5： | 7 |
| 2 | Index of microcirculatory resistance: state-of-the-art and potential applications in computational simulation of coronary artery disease显示文摘The dysfunction of coronary microcirculation is an important cause of coronary artery disease(CAD).The index of microcirculatory resistance(IMR)is a quantitative evaluation of coronary microcirculatory function,which provides a significant reference for the prediction,diagnosis,treatment,and prognosis of CAD.IMR also plays a key role in investigating the interaction between epicardial and microcirculatory dysfunctions,and is closely associated with coronary hemodynamic parameters such as flow rate,distal coronary pressure,and aortic pressure,which have been widely applied in computational studies of CAD.However,there is currently a lack of consensus across studies on the normal and pathological ranges of IMR.The relationships between IMR and coronary hemodynamic parameters have not been accurately quantified,which limits the application of IMR in computational CAD studies.In this paper,we discuss the research gaps between IMR and its potential applications in the computational simulation of CAD.Computational simulation based on the combination of IMR and other hemodynamic parameters is a promising technology to improve the diagnosis and guide clinical trials of CAD. | Yingyi GENG Xintong WU Haipeng LIU Dingchang ZHENG Ling XIA | 2022 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2022，23，2： | 1 |
| 3 | Electromagnetic anisotropic homogeneous model for eddy-current field in single-phase wound core显示文摘The analysis of the eddy-current field in the wound core widely used in the field of transformer energy conservation is taken as the theme.Adopting the homogenisation idea to consider the unique geometry of the wound core and features of its equivalent multi-stage circular cross-section magnetic boundary,a homogeneous model consisting of a columnar material with continuous homogeneous electromagnetic anisotropy is established by deriving the Maxwell equations of the magnetic quasi-static field in the columnar coordinate system.Finally,a homogeneous fine element model for the eddycurrent field in the wound core is established and the accuracy of the model has been verified by the test platform.The result shows that the homogeneous model can be effectively used for the analysis of the eddy-current field in the wound core,and the error of calculating the eddy-current loss under different excitation conditions is less than 6%under the premise of extremely saving the engineering calculation cost,which will help improve the operational performance of the wound core and contribute to the energysaving goal of the high-voltage equipment. | Lijun Zhou Woyang Li Yingyi Xia Jiawei Chen Chenqingyu Zhang Xiaohu Cai Lei Guo Dongyang Wang | 2024 | High Voltage2024，9，1： | 0 |
| 4 | Purpurolide C-based microneedle promotes macrophage-mediated diabetic wound healing via inhibiting TLR4-MD2 dimerization and MYD88 phosphorylation显示文摘Delayed wound healing in diabetes is a global challenge,and the development of related drugs is a clinical problem to be solved.In this study,purpurolide C(PC),a small-molecule secondary metabolite of the endophytic fungus Penicillium purpurogenum,was found to promote diabetic wound healing.To investigate the key regulation targets of PC,in vitro RNA-seq,molecular docking calcula-tions,TLR4-MD2 dimerization SDS-PAGE detection,and surface plasmon resonance(SPR)were per-formed,indicating that PC inhibited inflammatory macrophage activation by inhibiting both TLR4-MD2 dimerization and MYD88 phosphorylation.Tlr4 knockout in vivo attenuated the promotion effect of PC on wound healing.Furthermore,a delivery system consisting of macrophage liposome and GelMA-based microneedle patches combined with PC(PC@MLIP MN)was developed,which overcame the poor water solubility and weak skin permeability of PC,so that successfully punctured the skin and delivered PC to local tissues,and accurately regulated macrophage polarization in diabetic wound management.Overall,PC is an anti-inflammatory small molecule compound with a well-defined structure and dualtarget regulation,and the PC@MLIP MN is a promising novel biomaterial for the management of diabetic wound. | Yitong Liu Guiyang Xia Yingyi Chen Huan Xia Junji Xu Lijia Guo Sheng Lin Yi Liu | 2023 | Acta Pharmaceutica Sinica B2023，13，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员